Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Fallopian Tube Carcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian High Grade Serous Adenocarcinoma|Ovarian Serous Adenocarcinoma|Ovarian Serous Surface Papillary Adenocarcinoma|Primary Peritoneal Serous Adenocarcinoma|Triple-Negative Breast Carcinoma
Interventions: PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|DRUG: Cediranib Maleate|PROCEDURE: Computed Tomography|PROCEDURE: Echocardiography|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Multigated Acquisition Scan|DRUG: Olaparib
Sponsor: National Cancer Institute (NCI)